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Abstract
Thioredoxin (Trx) and thioredoxin reductase 1 (TR1) are among the major redox regulators in mammalian cells and
have a wide variety of roles, including removal of intracellular reactive oxygen species (ROS) and prevention of cell
death. Tumor necrosis factor-α (TNF-α) induces cancer cell death. Although ROS have been proposed to participate
in this process, the role of the thioredoxin system in TNF-α stimulated cell death remains unclear. We investigated
the possibility that the thioredoxin system protects against TNF-α-induced cancer cell death by examining whether
TR1/Trx1 status controls TNF-α-induced apoptosis in EMT6 murine breast cancer cells. TR1-deficient cells were
more sensitive to TNF-α than control cells. Increased sensitivity to TNF-α was most pronounced in Trx1-deficient
cells. TNF-α-induced nuclear localization of phosphorylated ERK 1/2 (p-ERK 1/2) correlated with increased apoptosis
in TR1- and Trx1-deficient cells, suggesting a pro-apoptotic role for nuclear p-ERK 1/2 in TNF-α-induced apoptosis.
In addition, phosphoinositide 3-kinase (PI3K) inhibition dramatically reduced TNF-α-stimulated apoptosis and nuclear
localization of p-ERK 1/2. In contrast, inhibition of ROS, MEK, JNK, or p38 did not significantly alter p-ERK 1/2
localization or apoptosis in TR1- and Trx1-deficient cells compared to control cells. Further, NF-κB p65 localization
was not changed in TR1- and Trx1-deficient cells in response to TNF-α relative to control cells. Our data suggest that
the thioredoxin system plays a critical role in protecting against TNF-α-induced apoptosis by regulating the levels of
nuclear p-ERK 1/2 in a PI3K-dependent manner.
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Introduction
The thioredoxin system is one of the most important cellular
redox regulatory systems. Thioredoxin (Trx) and thioredoxin
reductase 1 (TR1) are the principal components of this system.
The thioredoxin system regulates the redox state of protein
thiols and controls many cellular processes, including
proliferation, defense against oxidative stress, and apoptosis
[1–3]. Trx was first identified as a reductant for ribonucleotide
reductase and a regulator of DNA synthesis [4,5]. However, Trx
is now known to regulate many proteins in a variety of
pathways. The molecular and biological targets of Trx include
methionine sulfoxide reductase, which is involved in protein
repair [6,7], nuclear factor-kappa B (NF-κB) and apoptosis
signal-regulating kinase 1 (ASK1), which regulate apoptosis
[8,9], and peroxiredoxin, which regulates levels of reactive
oxygen species (ROS) [10].
Mammalian TR1 is a selenium-containing protein that has
selenocysteine (Sec), the 21st amino acid, at its catalytic site.
Sec is essential for the activity of TR1 [11,12]. TR1 is primarily
known for its ability to catalyze the transfer of reducing
potentials to thioredoxin from NADPH. However, TR1 has
additional substrates, including selenocompounds, ascorbate,
lipoate, and oxidized lipids. Thus, TR1 may regulate multiple
cellular processes in addition to reducing Trx and, through
function, regulate the cellular redox status [13–15]. Importantly,
TR1 has been shown to be over-expressed in many human
tumors and cancer cell lines. Numerous inhibitors of TR1 have
been reported to impede tumor growth, suggesting that this
selenoprotein may be a target for cancer therapy [16,17].
Indeed, knockdown of TR1 with small interfering RNA (siRNA)
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technology reversed many cancer phenotypes, providing
further evidence that this antioxidant enzyme plays an
important role in the progression and/or maintenance of cancer
[18,19]. Cancer cells are also known to be more sensitive to
selenite than normal cells. It was recently reported that TR1-
deficient cancer cells were far more sensitive to selenite than
the corresponding TR1-expressing cells [20]. These studies
suggest that TR1 function may protect cells from extracellular
stress. These data also uncovered a new role for TR1 in
cancer, which is compensated for by the glutathione system
and independent from its role in Trx1 reduction [21].
Extracellular signal-regulated kinases 1/2 (ERK 1/2) are part
of one of the mitogen-activated protein kinase (MAPK)
cascades, which regulate numerous cellular processes [22].
Exogenous stimulation of transmembrane receptors induces
ERK signaling via molecules such as Raf and MEK. ERK
signaling promotes multiple biological effects, such as
proliferation, differentiation, survival, apoptosis, and
morphology determination. It is not clear, however, how the
ERK cascade discriminates between different stimuli or how
activation of a single ERK cascade leads to different biological
consequences. Differences in the intensity, duration, and
cellular localization of ERK signaling may determine
downstream signaling and biological effects. ERK 1/2 are
localized predominantly in the cytoplasm of resting cells and
are translocated to different cellular compartments, such as the
nucleus, mitochondria, and endosomes upon stimulation
[22,23]. Nuclear ERK 1/2 phosphorylate transcription factors
that mediate a variety of physiological processes, including
chromatin reorganization [24,25]. In addition, activated ERK 1/2
interact with proteins, such as β-arrestin and the p14-MP1
complex, and migrate to early or late endosomes. ERK1/2
regulate the trafficking of endosomes and internalized
receptors [26,27]. ERK 1/2 were also found to localize to
mitochondria and regulate processes including cell survival,
apoptosis, and steroid synthesis [28,29].
To elucidate the role of TR1 and Trx1 in tumor necrosis
factor (TNF)-α-induced apoptosis in cancer cells, we examined
the sensitivity of TR1- or Trx1-deficient breast cancer cells to
TNF-α. TR1 deficiency sensitized cells to TNF-α, and Trx1
deficiency resulted in an extremely high sensitivity to TNF-α.
Levels of nuclear phospho-ERK 1/2 (p-ERK 1/2) were induced
by TNF-α. The most significant increases in nuclear localization
of p-ERK 1/2 were observed in cells that lacked TR1 and Trx1.
In contrast, PI3K inhibition diminished levels of nuclear p-ERK
1/2 and rescued cells from TNF-α-induced apoptosis. Thus,
abrogation of the thioredoxin system increased nuclear
localization of p-ERK 1/2 and significantly increased apoptosis
in response to TNF-α stimulation.
Materials and Methods
Materials
Recombinant mouse TNF-α, propidium iodide (PI), NuPage
4-12% Bis-Tris gels, polyvinylidene difluoride (PVDF)
membrane, hygromycin B, Lipofectamine 2000, Waymouth’s
MB 752/1 medium, antibiotic-antimycotic solution, and fetal
bovine serum (FBS) were obtained from Invitrogen Life
Technologies. PD98059, SB203580, JNK inhibitor II, and
LY294002 were purchased from EMD Millipore Bioscience.
The siRNA vector pSilencer 2.1-U6 Hygro was from Ambion,
Inc. Antibodies against cleaved caspase-3 and phosphorylated
and total ERK 1/2, p38, and JNK 1/2 were obtained from Cell
Signaling Technology, Inc. The antibody against TR1 was from
Epitomics. An anti-Trx1 antibody was from Abcam, Inc. The
anti-p65 antibody was from Santa Cruz Biotechnology, Inc.
Qproteome Mitochondria Isolation kit was purchased from
QIAGEN. The BCA protein assay reagent and SuperSignal
West Dura Extended Duration Substrate were from Thermo
Fisher Scientific Inc. Protease inhibitor and phosphatase
inhibitor cocktails were from Roche Diagnostics.
Stable knockdown of TR1 and Trx1 in EMT6 cells and
cell viability assay
The mouse mammary carcinoma cell line, EMT6, was
obtained from the American Type Culture Collection. Cells
were grown in Waymouth’s MB 752/1 media supplemented
with 15% FBS and an antibiotic-antimycotic solution in a
humidified incubator at 37°C with 5% CO2. Cells were stably
transfected with pU6m3 (control), siTR1 (TR1 knockdown), and
siTrx1 (Trx1 knockdown) constructs and were designated EMT/
pU6m3, EMT/siTR1, and EMT/siTrx1, respectively, as
previously described [20]. To measure sensitivity to TNF-α
treatment, 1.0×106 cells/dish were seeded onto 60-mm dishes
and incubated overnight. Cells were left untreated or treated
with TNF-α (10 ng/ml) for 48 h and harvested after washing
with phosphate-buffered saline (PBS). Cell viability was
measured by the trypan blue exclusion method. A Student’s t
test was used to calculate the statistical significance of the
experimental data.
Preparation of nuclear, cytosolic, and mitochondrial
extracts and western blot analysis
Cells were seeded onto a cell culture dish (1.0×106/60-mm
dish) and incubated overnight before treating with TNF-α (10
ng/ml). Cells were incubated for 10, 30, or 60 min and
harvested after washing twice with PBS. To examine the
effects of MAPK and PI3K inhibitors on the cellular localization
of p-ERK 1/2, cells were treated with ERK inhibitor (PD98059,
10 μM), p38 inhibitor (SB203580, 5 μM), JNK inhibitor II (10
μM), PI3K inhibitor (LY294002, 5 μM), or buffer for 1 h and
treated with TNF-α for 10 min. Cells were harvested after
washing twice with PBS. All western blots were carried out in
duplicate and representative data are shown in the figures.
Whole-cell protein samples were prepared with lysis buffer
(10 mM HEPES, pH 7.9, 10 mM KCl, 0.1 mM EGTA, 0.1 mM
EDTA, 1 mM dithiothreitol (DTT), protease inhibitor cocktail,
and phosphatase inhibitor cocktail) as described elsewhere
[18]. Nuclear extracts were prepared as described previously
[30]. In brief, harvested cells were incubated on ice for 10 min,
ruptured by vortexing for 10 sec after adding Igepal (0.3% final
concentration), and centrifuged at 13,000 × g for 1 min at 4°C.
Pellets, which contained nuclei, were suspended with nuclear
extraction buffer (20 mM HEPES, pH 7.9, 0.5 mM EGTA, 0.5
mM EDTA, 420 mM NaCl, 1 mM DTT, protease inhibitors, and
phosphatase inhibitors), incubated on ice for 30 min with
Trx Defects Increase TNF-α-Induced Apoptosis
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e71427
intermittent vortexing, and centrifuged at 13,000 × g for 15 min
at 4°C. Mitochondrial extracts were prepared with Qproteome
mitochondria isolation kit following the manufacturer’s
instructions. Protein concentrations were quantified with BCA
protein assay reagent. Protein samples were electrophoresed
on NuPAGE 4-12% Bis-Tris gels, and the separated protein
samples were transferred to a PVDF membrane. The
membrane was incubated with a primary antibody and washed
with TBS-T. The membrane was incubated with a horseradish
peroxidase-conjugated secondary antibody, exposed to
SuperSignal West Dura Extended Duration Substrate, and
visualized on X-ray film. The corresponding uncropped figures
of western blots presented in the text (Figures 1A, 1C, 2A, 2B,
3, 4A and 4B) are shown as Figure S4.
Quantification of apoptotic cells by flow cytometry
Cells (1.5×106/60-mm dish) were seeded onto culture dishes
and incubated overnight. Cells were pre-treated with ERK
inhibitor (PD98059, 10 μM), p38 inhibitor (SB203580, 5 μM),
JNK inhibitor II (10 μM), PI3K inhibitor (LY294002, 5 μM), or
buffer for 1 h and treated with TNF-α for 24 h. Cells were
harvested and fixed with cold 70% ethanol overnight at 4°C.
Fixed cells were centrifuged, re-suspended in PBS containing
RNase A, and incubated for 30 min at 37°C. Cells were stained
overnight in the dark with PI (50 μg/ml) and analyzed by flow
cytometry on a FACS Calibur 2 Sorter (Becton Dickinson). The
apoptotic cell populations were quantified by analyzing data
with FlowJo (Tree Star, Inc.).
Figure 1.  Knockdown of TR1 or Trx1 increases TNF-α-induced apoptosis in EMT6 cells.  (A) EMT6 cells were stably
transfected with pU6m3 (control), siTR1, or siTrx1 vectors, and expression levels of TR1 and Trx1 were analyzed by western
blotting. β-Actin was examined as a loading control. (B) The viabilities of EMT/pU6m3, EMT/siTR1, and EMT/siTrx1 after TNF-α
treatment (10 ng/ml) for 48 h were measured by staining with trypan blue and counting live cells. Darkened bars indicate untreated
cells, and clear bars indicate TNF-α -treated cells. Values show the numbers of viable cells and are the means ±S.D (p<0.01). (C)
EMT/pU6m3, EMT/siTR1, and EMT/siTrx1 cells were treated or untreated with TNF-α, and the level of cleaved capase-3 was
detected in cell extracts by western blotting. (D) Cells were untreated or treated with TNF-α. DNA was stained with PI, and the DNA
content was measured by flow cytometry. The percentages of apoptotic cells are shown in the graphs. The upper graphs show
untreated cells, and the lower graphs show treated cells. Experimental details for each study are given in the Materials and
Methods.
doi: 10.1371/journal.pone.0071427.g001
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Results
Generation of EMT6 cells with stable knockdown of
TR1 or Trx1
We stably knocked down TR1 or Trx1 in EMT6 cells with
siRNA constructs that have previously been shown to be
efficient in decreasing TR1 or Trx1 expression (Figure 1A) [20].
Expression of TR1 or Trx1 was down-regulated by more than
90% in stable EMT/siTR1 and EMT/siTrx1 cells, respectively, in
comparison to control cells expressing EMT/pU6m3 empty
vector. Interestingly, an increase in Trx1 expression was
Figure 2.  PI3K inhibition blocks TNF-α-induced apoptosis in EMT/pU6m3, EMT/siTR1, and EMT/siTrx1 cells.  (A) Cells were
untreated or treated with TNF-α (10 ng/ml) for the indicated time intervals. Phosphorylated (upper panels) and total ERK 1/2, p38,
and JNK 1/2 (lower panels) were measured by western blotting. (B) Cells were pre-treated with PI3K inhibitor, LY294002 (5 µM,
designated LY), JNK inhibitor II (10 μM, designated JI), NAC (0.5 mM), or buffer and treated with TNF-α. Cleaved caspase-3 was
measured by western blotting. (C) Cells were pre-treated with buffer, JNK inhibitor II (JI) or LY294002 (LY) and then treated with
TNF-α. The percentages of apoptotic cells were measured by flow cytometry and are shown in the graphs. Experimental details for
each study are given in the Materials and Methods. Experiments were carried out in duplicate and representative data are shown.
doi: 10.1371/journal.pone.0071427.g002
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observed upon knockdown of TR1, whereas Trx1 knockdown
did not cause a significant change in TR1 levels.
TNF-α-induced apoptosis is increased in TR1- or Trx1-
deficient cells
Because TNF-α induces cell death [31], the relative
sensitivities of the control, TR1-deficient, and Trx1-deficient
cells to TNF-α were examined (Figure 1B). In comparison to
untreated cells, approximately 80%, 50%, and 15% of the
control, TR1-deficient, and Trx1-deficient cells, respectively,
survived. Although the TR1-deficient and Trx1-deficient cells
both showed increased sensitivity to TNF-α versus control
cells, Trx1-deficient cells were the most sensitive.
To determine if the increased sensitivities of TR1-deficient or
Trx1-deficient cells to TNF-α were a reflection of increased
apoptosis, we examined activation of caspase-3, which is a
major marker of apoptosis. Full length caspase-3 must be
cleaved to become an active protease that mediates apoptosis
[32,33]. Caspase-3 activation by TNF-α was examined by
western blot analysis in the stable cell lines (Figure 1C).
Caspase-3 was activated in each of the cell lines. However, the
levels of cleaved caspase-3 were higher in TR1-deficient cells
relative to control cells and were even more pronounced in
Trx1-deficient cells.
Apoptosis was also examined after TNF-α treatment in each
cell line by analyzing cellular DNA content by flow cytometry
(Figure 1D). The percentages of apoptotic cells were
approximately 25%, 34%, and 60% for control, TR1-deficient,
and Trx1-deficient cells, respectively. The relative levels of
caspase-3 correlated with the levels of apoptosis. These data
suggested that reduced viability (Figure 1B) was due to
induction of apoptosis in response to TNF-α treatment.
Inhibition of PI3K with LY294002 rescues TNF-α-
induced apoptosis in TR1- and Trx1-deficient cells
TNF-α activates NF-κB and promotes nuclear translocation
of p65, which suppresses TNF-α-induced apoptosis [34] and
activates the MAPK pathways inducing various biological
process such as inflammation, proliferation and cell death
[35,36]. To assess the involvement of increasingly higher levels
Figure 3.  Phosphorylated ERK 1/2 is localized to the nucleus after TNF-α treatment.  EMT/pU6m3, EMT/siTR1, and EMT/
siTrx1 cells were exposed to buffer or TNF-α for the indicated time intervals. Cytosolic, nuclear, and mitochondrial protein extracts
were western blotted for phosphorylated and total ERK 1/2 and are shown in the upper, middle, and lower panels, respectively.
doi: 10.1371/journal.pone.0071427.g003
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Figure 4.  PI3K inhibition blocks TNF-α-induced nuclear re-localization of p-ERK 1/2.  EMT/pU6m3, EMT/siTR1, and EMT/
siTrx1 cells were initially treated or untreated with LY294002 (5 μM, designated LY) for 1 h and treated or untreated with TNF-α. (A)
Phosphorylated and total ERK 1/2, p38, and JNK were measured in total cellular lysates by western blotting (B) Phosphorylated and
total ERK 1/2 in nuclear (upper), cytosolic (middle), and mitochondrial (lower) fractions were measured by western blotting.
doi: 10.1371/journal.pone.0071427.g004
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of apoptosis in TR1- and Trx1-deficient cells than control cells
induced by TNF-α, the amount of p65 imported into the nucleus
following TNF-α treatment in the three cell lines was initially
examined (Figure S1A). p65 levels increased substantially in
the nucleus at 10 min, appeared to decline at 30 min and were
virtually absent at 60 min in each cell line. Simultaneously, the
levels in the cytoplasm appeared to decrease at 10 min and
then increase by 60 min in an approximate balanced manner
between the nucleus and cytoplasm over the course of the
experiment. But TR1 or Trx1 deficiencies did not lead to any
significant change in the nuclear translocation of p65 by TNF-α
treatment compared to the corresponding control.
Activation of the MAPK proteins, ERK 1/2, p38 and JNK 1/2,
which occurs upon their phosphorylation, was next examined
(Figure 2A). These three MAPKs were strongly phosphorylated
at 10 min and quickly deactivated in each cell line with the
exception of phosphorylated p38 that was maintained up to 60
min in Trx1-deficient cells. The levels of ERK 1/2 and JNK 1/2
prior to phosphorylation were substantially higher in Trx1-
deficient cells compared to the other two cell lines, and the
possible reason for this enrichment was unclear.
Because the PI3K pathway is known to affect ERK 1/2
signaling cascade [37], the involvement of MAPK and PI3K
pathways with the enhanced apoptosis caused by TR1- or
Trx1-deficient cells was further investigated. The effects of an
ERK 1/2 inhibitor, PD98059, a JNK 1/2 inhibitor, JNK inhibitor
II, a p38 inhibitor, SB203580, and a PI3K inhibitor, LY294002,
on TNF-α-induced caspase-3 activation were examined.
Inhibition of ERK 1/2 or p38 increased caspase-3 activation
(Figure S1B). In contrast, LY294002 almost completely blocked
caspase-3 activation in all three cell lines (Figure 2B, upper
panel). JNK inhibition did not significantly affect caspase-3
activation (Figure 2B, middle panel). Because the thioredoxin
system is primarily known as a regulator of cellular redox
status, the involvement of ROS in TNF-α-induced apoptosis
was examined (Figure 2B, lower panel). Cells were treated with
an ROS inhibitor, NAC (N-acetyl cysteine), and caspase-3
activation was assessed by western blotting. NAC did not alter
caspase-3 activation, suggesting that ROS did not play a major
role in mediating the increased apoptosis of TR1- and Trx1-
deficient cells.
To confirm the data regarding kinase inhibition and
caspase-3 activation, we examined the effects of kinase
inhibitors on apoptosis in TR1- and Trx1-deficient cells
following TNF-α treatment. Inhibition of ERK 1/2 and p38,
which increased caspase-3 activation, also resulted in a slight
increase in apoptosis in control and TR1-deficient cells and
virtually no change in Trx1-deficient cells (Figure S2). However,
JNK inhibition, which did not affect caspase-3 activation,
resulted in a slight rescue from apoptosis in TR1- and Trx1-
deficient cells, Treatment with LY294002, which completely
blocked the activation of caspase-3, dramatically rescued
apoptosis in all three cell lines (Figure 2C, columns 3 and 4,
respectively). A small percentage of LY294002-treated, TNF-α-
stimulated Trx1-deficient cells were apoptotic.
Knockdown of TR1 or Trx1 increases TNF-α-induced
nuclear localization of p-ERK 1/2
ERK 1/2 is known to translocate to the nucleus and
mitochondria upon activation by various stimuli [22,23]. The
amounts of p-ERK 1/2 were measured in the nucleus, cytosol,
and mitochondria to determine if localization of p-ERK 1/2
contributes to the enhanced sensitivity of TR1- and Trx1-
deficient cells to TNF-α (Figure 3). Phosphorylation of ERK 1/2
was induced within 10 min of TNF-α treatment in all three
cellular compartments similar to total p-ERK 1/2 (compare
Figure 3 with Figure 2A, upper panel). Similar levels of
cytosolic and mitochondrial p-ERK 1/2 were observed in control
and Trx1-deficient cells, whereas TR1-deficient cells had the
lowest level of mitochondrial p-ERK 1/2. Importantly, the
amounts of p-ERK 1/2 in the nucleus were significantly higher
in TR1-deficient cells and highest in Trx1-deficient cells, which
suggested a correlation between levels of nuclear p-ERK 1/2
and apoptosis following TNF-α treatment.
Inhibition of PI3K blocks TNF-α-induced nuclear
localization of p-ERK 1/2
Because PI3K inhibition rescued cells from apoptosis (Figure
2B and 2C), the role of PI3K in the nuclear localization of p-
ERK 1/2 was examined (Figure 4). The effects of LY294002 on
ERK 1/2 phosphorylation in total cellular lysates (Figure 4A)
was compared to p-ERK 1/2 in cellular compartments (Figure
4B). Inhibition of PI3K before TNF-α treatment did not cause a
significant change in total p-ERK 1/2. However, LY294002
increased the levels of phosphorylated p38 and JNK 1/2
(Figure 4A). The amounts of p-ERK 1/2 in the cytosol and
mitochondria were slightly affected by LY294002 treatment,
whereas mitochondrial p-ERK 1/2 in TR1-deficient cells was
diminished (Figure 4B, middle and lower panels). As expected,
inhibition of PI3K prior to TNF-α treatment almost completely
abolished the increased level of nuclear p-ERK 1/2 (Figure 4B,
upper panel).
Discussion
The thioredoxin system is an important molecular target for
anti-cancer therapy. Increased expression levels of TR1 and
Trx1 have been reported in various cancer models in
association with poor prognosis, increased proliferation, and
high tumor grade [38–40]. We previously reported that TR1 has
a role in promoting or maintaining cancer. Knockdown of TR1
has been shown to reduce anchorage-independent growth,
tumor growth, metastasis, and self-sufficient growth signaling in
cancer cells [18,19]. These studies support inhibition of the
thioredoxin system as a therapeutic strategy in cancer.
However, the mechanistic basis by which the thioredoxin
system inhibition suppresses cancer progression remains
unclear.
In this study, we present data that suggest that loss of Trx1
or TR1 increases TNF-α-induced apoptosis in breast cancer
cells by localizing phosphorylated ERK 1/2 to the nucleus in a
PI3K-dependent manner. Stable knockdown of TR1 or Trx1
caused increased caspase-3 cleavage, reduced cell survival,
and increased apoptosis in response to TNF-α relative to
Trx Defects Increase TNF-α-Induced Apoptosis
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control cells. Increased apoptosis of thioredoxin system-
defective cells was associated with significantly increased
levels of nuclear p-ERK 1/2. In contrast, cytosolic and
mitochondrial p-ERK 1/2 did not correlate with the increased
sensitivity of TR1- and Trx1-deficient cells to TNF-α. These
results suggest that cellular localization of p-ERK 1/2 is a
critical determinant of whether cells with defective thioredoxin
function will undergo apoptosis in response to particular stimuli,
such as TNF-α.
Phosphorylation of ERK 1/2 is regulated in part by PI3K
signaling [37]. Thus, we examined the effect of PI3K inhibition
on the cellular localization of p-ERK 1/2. We found that PI3K
inhibition prevented TNF-α-induced apoptosis in association
with localization of p-ERK 1/2. Levels of nuclear p-ERK 1/2
were almost completely suppressed by PI3K inhibition,
whereas cytosolic and mitochondrial p-ERK 1/2 levels were
only slightly affected by LY294002. These observations
suggested that PI3K signaling regulated TNF-α-induced
apoptosis by controlling nuclear localization of p-ERK 1/2. The
specificity of PI3K signaling involvement in this process was
supported by data showing that inhibition of MEK or p38 MAPK
did not significantly alter TNF-α-induced apoptosis in
thioredoxin-defective cells relative to control cells. Further,
although MAPK and NF-κB were strongly activated by TNF-α,
there were not significant differences between TR1- or Trx1-
deficient cells and control cells. The effects of MAPK inhibitors
on caspase-3 activation and apoptosis did not correlate with
the increased sensitivity of TR1- or Trx1-deficient cells.
Importantly, however, inhibition of PI3K with LY294002 almost
completely blocked caspase-3 activation in all of three cell lines
and rescued virtually all of the control and TR1-deficient cells
from apoptosis. In addition, ~65% of the apoptotic cells were
recovered by inhibiting PI3K in Trx1-deficient cells. These latter
observations suggested that PI3K plays a major role in
regulating TNF-α-induced apoptosis. Trx1 deficiency also
appeared to cause additional defects in these cells, resulting in
greater sensitivity to TNF-α.
The specific down-regulation of nuclear p-ERK 1/2
subsequent to PI3K inhibition resulted in an almost complete
recovery from apoptosis. These data suggest a pro-apoptotic
role for nuclear p-ERK 1/2 and an anti-apoptotic role for p-ERK
1/2 localized in other cellular compartments. PI3K has been
shown to affect the activity of ERK 1/2. Tropomyosin-1-induced
microfilaments and RhoA were involved in nuclear localization
of ERK 1/2 [41,42]. ASK1 is an example of kinase whose
activity is controlled by interaction with Trx, wherein the binding
is dependent on the redox status of Trx. Many other kinases
and phosphatases have been reported to be regulated by Trx,
but in most cases the mechanisms are poorly understood [2].
Casein kinase 2 also regulated the nuclear transport of ERK
1/2 by phosphorylating two Ser residues within a nuclear
translocation signal [43]. Trx1 deficiency inhibited the activation
and the nuclear localization of ERK 1/2 after epidermal growth
factor (EGF) treatment, but the role of nuclear ERK 1/2 was not
examined [44]. The function and mechanism of PI3K in the
translocation of ERK 1/2 to specific cellular organelles requires
further investigation. In contrast to nuclear p-ERK 1/2, total
nuclear ERK 1/2 was not significantly altered by TNF-α
treatment. Similarly, cytosolic and mitochondrial ERK 1/2 levels
were unchanged in response to TNF-α. Thus, TNF-α-
stimulated breast cancer cells that have lost TR1 or Trx1
showed specific localization of p-ERK 1/2 to the nucleus in
association with apoptosis. Further investigation will establish
the upstream pathways that activate PI3K signaling and
additional mechanisms regulating ERK 1/2 translocation to
specific cellular organelles in TR1- and Trx1-deficient cells.
Another important mechanism of TNF-α-induced apoptosis is
the induction of ROS levels via NADPH oxidase (NOX)
activation. Pre-treatment with NAC decreases ROS induction in
response to TNF-α stimulation [45,46]. However, we found that
pre-treatment of cells with NAC prior to TNF-α treatment did
not affect caspase-3 activation, suggesting that ROS did not
significantly contribute to TNF-α-induced apoptosis in EMT6/
TR1- or Trx1-deficient cells. Activation of NF-κB is also known
to suppress TNF-α-induced apoptosis [34]. However, p65
localization to the nucleus, which is an indication of activation,
was not altered by MAPK or PI3K inhibition after TNF-α
treatment (Figure S3). Thus, PI3K inhibition appeared to
rescue TNF-α-induced apoptosis in an NF-κB-independent
manner.
Our data further indicated that cells with Trx1 knockdown
showed a more significant reduction in cell survival (15%) than
TR1-deficient cells (50%). A similar trend was observed with
caspase-3 activation and apoptosis. Previous studies have
shown that TR1 knockdown led to a significantly higher level of
selenium cytotoxicity in mouse DT cells in comparison to Trx1
loss in these cells [20]. The enhanced cytotoxicity of selenium
in TR1-deficient cells was caused by increased production of
glutathione, suggesting that TR1 regulates glutathione
production and secretion in a Trx1-independent manner. Trx1-
deficient breast cancer cells manifested a particularly high
sensitivity to TNF-α-induced apoptosis. These results support a
protective or anti-apoptotic role for the thioredoxin system. In
addition, our data demonstrate dependence of TR1 on Trx1 in
protecting cells against TNF-α-induced apoptosis. Trx regulates
the activity of ASK1 which is one of the major apoptosis
regulators [2]. Future studies on the involvement of ASK1 in
PI3K signaling and regulation of TNF-α induced apoptosis by
controlling nuclear p-ERK1/2 may provide further insights into
the role of the thioredoxin system in apoptosis.
A potential limitation of the study was the use of a single
murine breast cancer cell line. However, EMT6 cells are a well-
established model system for studying molecular abnormalities
in breast cancer. Further studies will need to be performed in
human breast cancer cell lines. In particular, and due to the
critical role of PI3K signaling in the apoptotic response of TR1-
and Trx1-deficient cells, breast cancer cell lines that harbor
constitutive activation of the PI3K signaling pathway will also
need to be examined. A subset of human breast cancers are
known to express PIK3CA hyper-activating mutations or loss of
the PTEN phosphatase, resulting in constitutively activated
PI3K [47,48]. Our data suggested that PI3K signaling mediates
the heightened apoptotic response to TNF-α in cells with
defective thioredoxin systems. Thus, one can hypothesize that
inhibition of TR1, and especially Trx1, may be a highly effective
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strategy for inducing apoptosis in breast cancer cells that
harbor endogenous hyper-activation of PI3K signaling.
In summary, the following novel findings were made with the
cancer cell lines with stable knockdown of the thioredoxin
system(1). Loss of thioredoxin function increased the apoptotic
response of murine breast cancer cells to TNF-α(2). Levels of
nuclear p-ERK 1/2 were increased in association with
apoptosis in TNF-α-treated thioredoxin-defective cells(3). TNF-
α-induced apoptosis and localization of nuclear p-ERK 1/2
were dependent upon PI3K signaling. Thus, abrogation of the
thioredoxin system enhanced sensitivity to TNF-α through a
PI3K-dependent mechanism involving localization of
phosphorylated ERK 1/2 to the nucleus. Our results provide
novel insights into the mechanisms by which inhibition of TR1
and Trx1 promotes apoptosis of cancer cells and strongly
support thioredoxin system blockade as a novel therapeutic
strategy for cancer.
Supporting Information
Figure S1.  Nuclear translocation of p65 by TNF-α
treatment and the effect of MAPK inhibitors on TNF-α-
induced caspase-3 activation. (A) EMT/pU6m3, EMT/siTR1,
and EMT/siTrx1 cells were untreated or treated with TNF-α for
the indicated time intervals. Cytosolic and nuclear extracts
were prepared as stated in the Materials and Methods section.
Expression of p65 was measured by western blotting. (B) Cells
were pre-treated with PD98059 (PD) or SB203580 (SB) for 1 h
and treated with TNF-α. Cleaved caspase-3 was examined
after 24 h by western blotting.
(PDF)
Figure S2.  Effect of PD98059 and SB209580 on TNF-α-
induced apoptosis. EMT/pU6m3, EMT/siTR1, and EMT/
siTrx1 cells were pre-treated with MEK inhibitor, PD98059 (10
μM, designated PD), and p38 inhibitor, SB203580 (5 μM,
designated SB), for 1 h and incubated with TNF-α. The
percentages of apoptotic cells were measured by examining
DNA contents after staining with PI and are shown in the
graphs. Experimental details are given in the Materials and
Methods section.
(PDF)
Figure S3.  Effect of MAPKs and PI3K inhibitors on the
nuclear translocation of p65 by TNF-α. Cells were pre-
treated with PD98059, SB203580, JNK inhibitor II, or
LY294002 and treated with TNF-α. Nuclear extracts were
western blotted for p65. Experimental details are given in the
Materials and Methods section.
(PDF)
Figure S4.  Uncropped figures of western blots presented
in the text (Figures 1A, 1C, 2A, 2B, 3, 4A and 4B).
(PDF)
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